INTRODUCTION
It is estimated that in 2016, there were almost 2.1 million (uncertainty bounds 1.4-2.7 million) adolescents (age 10-19 years) living with HIV [1], including 770 000 (uncertainty bounds 520 000-1.01 million) younger adolescents, age 10-14 years and 1.3 million (uncertainty bounds 870 000-1.68 million) older adolescents, age 15-19 years [2 && ]. Adolescents living with HIV (ALHIV) are a complex, heterogeneous population of children with peri/ postnatally acquired HIV ageing up into adolescence in combination with adolescents newly horizontally infected with HIV during adolescence [3 & ]. Peri/postnatally infected ALHIV (pALHIV) often have more advanced HIV disease with related comorbidities and disabilities associated with delayed HIV treatment and lifelong infection [4] . They may be highly antiretroviral therapy (ART)-experienced, having commenced ART during infancy or childhood, and are at a higher risk of treatment failure and mortality during adolescence [5] . However, horizontally infected ALHIV (hAL-HIV) may experience other social, economic and sexual health risk factors associated with acquiring HIV during adolescence [6] .
In common is that both pALHIV and hALHIV are navigating the developmental transition of adolescence while dealing with a chronic disease and sexually transmissible infection. They are a population at a greater risk of being lost to follow-up and ]. The estimated number of younger ALHIV has stabilized since 2014, likely corresponding with prevention of mother-tochild HIV transmission (PMTCT) programme expansion that has led to fewer new peri/postnatally infected children annually, while ALHIV are ageing up into older adolescence and young adulthood (Fig. 1 HIV is the eighth leading cause of adolescent deaths globally, the fourth leading cause in younger adolescent girls globally and the fourth leading cause of all adolescent mortality in African low and middleincome countries.
Despite receiving antiretroviral therapy, ALHIV still experience substantial morbidity and AIDS-related mortality. To better understand mortality in ALHIV in LMICs, we need to collect more detailed data that go beyond the biomedical cause of death to understand contributing structural, social, emotional and mental health factors.
There is a considerable population of ALHIV unaware of their HIV infection and, once diagnosed, ALHIV experience high rates of loss to follow-up. A priority for ALHIV must be earlier diagnosis and successful linkage to and retention in care so that they can initiate treatment and achieve sustained viral suppression to prevent avoidable morbidity and mortality.
Key investments during the turbulent but temporary phase of adolescence that would enhance our ability to track their outcomes so we can develop interventions to address them include systems for nationally and globally disaggregated adolescent data; collection of more granular data within the context of routine care settings to identify structural, social and mental health challenges during adolescence; and prioritizing viral load monitoring and differentiated models of care for ALHIV. [13] . Under the guidance of the UNAIDS Reference Group on Estimates, Modelling, and Projections, the model is continuously refined to incorporate the most up to date understanding of the HIV epidemic based on demographic, HIV epidemiologic and programmatic data (http://www.epidem.org/) [14 && ]. Estimates are generated on an annual basis and updated for the current and all historic years [15] . The UNAIDS modelled estimates for the numbers of adolescents newly HIV-infected, living with HIV and HIV-associated deaths provide a critical global-level resource that can be used to guide policy and programme planning, as well as prioritizing surveillance needs and research agendas. For a detailed description of the methods for the 2017 estimates see reference [12] . Current national, regional and global indicator estimates are available at http://aidsinfo.unaids.org.
females living with HIV, important sex-based differences are apparent in older ALHIV. In 2016, girls disproportionately accounted for 61% of older ALHIV, and 67% of new infections among older ALHIV [2 && ]. Furthermore, where 65% of older female ALHIV were estimated to have been horizontally infected, only 43% of older male ALHIV were horizontally infected (Fig. 2) [16] . These sex differences are particularly prominent in Eastern and Southern Africa, where 62% of older female ALHIV were estimated to be horizontally infected, compared with 28% of older male ALHIV (Fig. 3) [16] . Although the numbers of ageing pALHIV are steadily increasing with successful ART, their relative contribution to the global epidemic will depend in large part on our ability to prevent new horizontal adolescent infections.
Absolute numbers of deaths in younger ALHIV appear to be in decline, having peaked in 2010 at 32 000 (24 000-44 000) HIV-associated deaths and reduced to 27 000 (uncertainty bounds 19 000-37 000) in 2016 ( Fig. 1) 
Corresponding with the distribution of younger ALHIV, more than half of younger adolescent HIV-associated deaths in 2016 occurred in Eastern and Southern Africa [16 000 (uncertainty bounds 12 000-22 000)] and almost 90% in sub-Saharan Africa overall. However, unlike the reduction in absolute numbers of deaths that has been observed in children (0-14 years) and adults (15 years), the absolute number of deaths in older adolescents remained static at 28 000 (uncertainty bounds 20 000-39 000) per year since peaking in 2012 (Fig. 1) . With the steadily increasing size of the older ALHIV population, mortality rates, rather than absolute numbers, are required to accurately monitor survival trends of older ALHIV. Empiric studies following cohorts of ALHIV in high-income countries have been used to complement and inform the UNAIDS-supported modelled mortality estimates in ALHIV. Comparable studies in highburden low and middle-income countries (LMICs) will be necessary to provide mortality rate trends to validate the UNAIDS estimates in these regions going forward [3 & ]. Strengthening data disaggregated by age, sex and mode of HIV transmission would facilitate more granular monitoring of subpopulations of ALHIV who have differing risks for newly acquiring HIV and HIV-associated mortality, evidence required to develop effective interventions to mitigate these risks.
THE CONTRIBUTION OF HIV TO THE GLOBAL BURDEN OF ADOLESCENT DISEASE
HIV-associated mortality is an important contributor to global adolescent mortality. The WHO Global Health Estimates for 2015, published in 2016, reported that HIV was the eighth leading cause of death among all adolescents globally [17 && ]. In African LMICs, HIV was the fourth leading cause of all adolescent deaths, following lower respiratory tract infections, diarrhoeal disease and meningitis. Globally, in younger adolescent girls, HIV was the fourth leading cause of death, following lower respiratory tract infections, diarrheal disease and meningitis. In older adolescent girls, HIV was the eighth leading cause of death, with maternal causes of death leading in this group. In both younger and older adolescent males, traumatic deaths related to road injury, drowning or interpersonal violence predominated, with HIV being the seventh and 10th leading cause of death in younger and older adolescent boys, respectively [17 && ]. This heterogeneity in causes of adolescent death by age and sex highlights that the need for disaggregated adolescent data is not exclusive to HIV. Reorientation of health system monitoring and service provision that is sensitive to the rapidly changing needs of adolescents will have benefits for the well being of all adolescents, including ALHIV [18 && ]. Adolescent-specific health system policy implementation is starting to occur, the recently released South African National Adolescent and 
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Youth Health Policy being one example [19 && ]. However, such efforts need to be more widespread to improve the quality of care and outcomes for adolescents, particularly in the global pursuit of Sustainable Development Goal 3 to achieve health for all at all ages [20] .
HIV-ASSOCIATED MORTALITY AND MORBIDITY DURING ADOLESCENCE
To reduce HIV-associated mortality during adolescence, an understanding of the underlying causes of HIV-associated mortality and morbidity is needed to complement estimates of the numbers of deaths and where they are occurring. Evidence from multiple regions and research teams is converging around common findings of poorer outcomes among ALHIV in general, and for older youth in particular.
(1) In a study combining 1446 perinatally HIVinfected youth aged [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ]. By the end of the study period, 3% (N ¼ 94) of children had died. Despite these ALHIV having received ART, 64% of deaths were due to HIV-related infections, predominantly bacterial infection and/or sepsis and 27% were due to other HIV-related causes. Two suicides, recorded amongst other non-HIV related deaths, may be an unrecognized consequence of the mental health strains of growing up with HIV [23, 24] . [26] . The incidence of mortality was 1.12 (95% CI 0.75-1.67) and 0.68 (95% CI 0.49-0.94) per 100 person-years in older and younger adolescents, respectively [incidence rate ratio 1.65 (95% CI 0.94-2.84)]. Through a standardized cause of death reporting process, 58% of deaths were determined to have been due to underlying infectious causes, of which 46% were AIDS-related opportunistic infections, despite 95% of ALHIV being on ART at the time of death [26] .
Even with access to ART, ALHIV across the globe are dying from AIDS-related causes and experiencing substantial mental health and neurodevelopmental morbidity, including in settings wherein second and third-line ART are available. Furthermore, multiregional collaborations have identified that despite expansion of HIV services and access to ART, inequality in survival remains. Mortality of ALHIV on ART living in LMICs remains higher than ALHIV on ART in high-income countries [22 && ,27,28] . Geographic inequalities in combination with the burden of AIDS-related morbidity and mortality clearly indicate that survival for ALHIV is impacted by factors beyond access to ART [29] [30] [31] . These may include social and mental health factors such as adherence challenges, treatment fatigue and depression [30, 32] . To better understand mortality in ALHIV in LMICs, we need to collect more detailed data that go beyond the biomedical causes of death to understand contributing structural, social, emotional and mental health factors.
BURDEN OF UNDIAGNOSED AND UNRETAINED ADOLESCENTS LIVING WITH HIV
To realize the UNAIDS 90-90-90 targets for ALHIV, adolescents must first be diagnosed as HIV-infected to achieve the first target (90% know their HIV status) and must be retained in care to achieve the second (90% on ART) and third (90% virologically suppressed) targets. However, there is a considerable population of ALHIV unaware of their HIV infection and, once diagnosed, ALHIV experience high rates of loss to follow-up (LTFU). In a community survey conducted in 2013-2015, following implementation of optimized opt-out provider-initiated counselling and testing at primary healthcare clinics in Harare, Zimbabwe, 38% (95% CI 30-46%) of children and adolescents aged 8-17 years with positive HIV tests had not previously been diagnosed [33 & ]. Children were less likely to have been diagnosed if they were over 13 years of age, in good health and with both parents alive. These findings are consistent with population-level estimates from the Population Health Impact Assessment (PHIA) surveys in Zimbabwe and Swaziland that found youth aged 15-24 years to be less likely to know their HIV status and less likely to be on ART than older adults [34, 35] . Late diagnosis of HIV has major implications for the health and survival of these ALHIV [36 & ].
Once diagnosed, ALHIV struggle to remain in care. Older adolescents in Zimbabwe had higher LTFU rates than older children and younger adolescents (adjusted rate ratio 1.6, 95% CI 1.2-2.1) and starting ART during older adolescence was associated with a 1.7 (95% CI 1.1-2.8) times greater risk of LTFU than starting in any younger age group [11 & ]. Unlike for adults living with HIV, there are still evidence gaps to understand what proportion of LTFU in ALHIV is due to mortality as compared with other reasons for LTFU, such as undocumented transfer to care elsewhere [37] [38] [39] . Thus, the accuracy of survival estimates in ALHIV are limited where LTFU is high and mortality may be underestimated as unascertained deaths in those LTFU are often not adjusted for [27] . A priority for ALHIV must be earlier diagnosis and successful linkage to and retention in care so that they can initiate treatment and achieve sustained viral suppression to prevent avoidable morbidity and mortality.
THE PROMISE AND POTENTIAL OF DIFFERENTIATED SERVICE DELIVERY FOR ADOLESCENTS LIVING WITH HIV
Differentiated care is being widely promoted as a way to allow patients greater freedoms in managing their own care, shifting the locus of care into the community, where peer and healthcare worker led adherence clubs offer a more efficient and effective alternative to busy institutional settings [40, 41] . It also has the potential to substantially reduce national HIV programme costs and provider burden by decreasing the frequency of clinic visits for stable patients with evidence of viral suppression, when there are reliable supply chains to sustain multimonth medication refills [42, 43] . In Rwanda, programme implementers specifically created a visit schedule for virologically suppressed adolescents up to age 19 years that align 3-monthly clinical and medication pick-up visits with school breaks [44] . However, full implementation of these models requires routine viral load monitoring, which is infrequently available in much of sub-Saharan Africa [45] . There is a strong case to be made for prioritizing routine viral load monitoring for ALHIV, who are in a life stage wherein they are at a high risk for poor outcomes [46 && ].
Optimal approaches for differentiated care for adolescents who struggle with daily adherence, and are more often on second-line regimens, are less clear. Such youth are often given more frequent clinic visits, which can be perceived as punishment and include stern counselling that may engender guilt rather than encouragement [47] . Although the vast majority could benefit from differentiated care and maintain stable HIV disease, greater attention should be focused on studying how to modify care models for the minority of adolescents who need more proactive engagement [48 & ]. Although recent achievements in expanding treatment to 21 million people with HIV are to be celebrated, policies and programmes that do not directly address ALHIV struggles with long-term care will limit their chances for future treatment success and sustained health benefits [49] .
CONCLUSION
Adolescence is a turbulent, but temporary phase. Considering that ALHIV, whether peri/postnatally or horizontally infected, are the population that will be living with HIV for the longest span of their lives, strategic targeted investments during this transitional phase are warranted. Priority investments for monitoring ALHIV outcomes include strengthening systems for nationally and globally disaggregated adolescent data by age, sex and mode of transmission to monitor progress in reducing new infections and mortality in high-risk subpopulations of ALHIV; collection of more granular data within the context of routine care settings to identify structural, social and mental health challenges to being diagnosed with HIV, retained in care and maintaining viral suppression; prioritizing viral load monitoring for earlier identification of those with viral nonsuppression and treatment failure; and differentiated models of care to allow flexibility, freedom and independence for the majority of ALHIV that are retained in care and on stable ART.
